The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Bacillus Calmette-Guérin (BCG) Infection Following Intravesical BCG Administration as Adjunctive Therapy For Bladder Cancer: Incidence, Risk Factors, and Outcome in a Single-Institution Series and Review of the Literature
Open accessAbstract
Bacillus Calmette-Guérin (BCG) is the most effective intravesical immunotherapy for superficial bladder cancer. Although generally well tolerated, BCG-related infectious complications may occur following instillation. Much of the current knowledge about this complication comes from single case reports, with heterogeneous diagnostic and therapeutic approaches and no investigation on risk factors for its occurrence. We retrospectively analyzed 256 patients treated with intravesical BCG in our institution during a 6-year period, with a minimum follow-up of 6 months after the last instillation. We also conducted a comprehensive review and pooled analysis of additional cases reported in the literature since 1975. Eleven patients (4.3%) developed systemic BCG infection in our institution, with miliary tuberculosis as the most common form (6 cases). A 3-drug antituberculosis regimen was initiated in all but 1 patient, with a favorable outcome in 9/10 cases. There were no significant differences in the mean number of transurethral resections prior to the first instillation, the time interval between both procedures, the overall mean number of instillations, or the presence of underlying immunosuppression between patients with or without BCG infection. We included 282 patients in the pooled analysis (271 from the literature and 11 from our institution). Disseminated (34.4%), genitourinary (23.4%), and osteomuscular (19.9%) infections were the most common presentations of disease. Specimens for microbiologic diagnosis were obtained in 87.2% of cases, and the diagnostic performances for acid-fast staining, conventional culture, and polymerase chain reaction (PCR)-based assays were 25.3%, 40.9%, and 41.8%, respectively. Most patients (82.5%) received antituberculosis therapy for a median of 6.0 (interquartile range: 4.0-9.0) months. Patients with disseminated infection more commonly received antituberculosis therapy and adjuvant corticosteroids, whereas those with reactive arthritis were frequently treated only with nonsteroidal antiinflammatory drugs (p < 0.001 for all comparisons). Attributable mortality was higher for patients aged ≥65 years (7.4% vs 2.1%; p = 0.091) and those with disseminated infection (9.9% vs 3.0%; p = 0.040) and vascular involvement (16.7% vs 4.6%; p = 0.064). The scheduled BCG regimen was resumed in only 2 of 36 patients with available data (5.6%), with an uneventful outcome. In the absence of an apparent predictor of the development of disseminated BCG infection after intravesical therapy, and considering the protean variety of clinical manifestations, it is essential to keep a high index of suspicion to initiate adequate therapy promptly and to evaluate carefully the risk-benefit balance of resuming intravesical BCG immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer
Shelley, M. D., Court, J. B., Kynaston, H., Wilt, T. J., Coles, B., & MASON, M. D. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003231.pub2 · Cited by 86
RetractedIntracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors
Morales, A., Eidinger, D., & Bruce, A. W. (1976) · Journal of Urology · doi:10.1016/s0022-5347(17)58737-6 · Cited by 1,791
Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors
Morales, A., Eidinger, D., & Bruce, A. W. (2017) · Journal of Urology · doi:10.1016/j.juro.2016.10.101 · Cited by 1,533
SYLVESTER, R. J., van der MEIJDEN, A. P. M., & LAMM, D. L. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64273-5 · Cited by 1,312
Intracavitary bacillus Calmette-Grerin in the treatement of superficial bladder tumors
Morales, A. (1976) · The Journal of Urology · Cited by 978
Lamm, D. L., Van Der Meijden, A. P. M., Morales, A., Brosman, S. A., Catalona, W. J., Herr, H. W., Soloway, M. S., Steg, A., & Debruyne, F. M. J. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37316-0 · Cited by 786
Brausi, M., Oddens, J., Sylvester, R., Bono, A., van de Beek, C., van Andel, G., Gontero, P., Turkeri, L., Marreaud, S., Collette, S., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.07.021 · Cited by 389
Shelley, M. D., Wilt, T. J., Court, J., Coles, B., Kynaston, H., & Mason, M. D. (2004) · BJU International · doi:10.1111/j.1464-410x.2003.04655.x · Cited by 342
Immune Mechanisms in Bacillus Calmette-Guerin Immunotherapy for Superficial Bladder Cancer
BÖHLE, A., & BRANDAU, S. (2003) · Journal of Urology · doi:10.1097/01.ju.0000073852.24341.4a · Cited by 318
Smith, J. A. J., Labasky, R. F., Cockett, A. T. �., Fracchia, J. A., Montie, J. E., & Rowland, R. G. (1999) · PubMed · Cited by 215
Cited by
Mechanisms of BCG immunotherapy and its outlook for bladder cancer
Pettenati, C., & Ingersoll, M. A. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0055-4 · Cited by 457
Metadata
- Authors
- Pérez-Jacoiste Asín, M. A., Fernández-Ruiz, M., López-Medrano, F., Lumbreras, C., Tejido, Á., San Juan, R., Arrebola-Pajares, A., Lizasoain, M., Prieto, S., & Aguado, J. M.
- Venue
- Medicine
- Published
- 2014-10
- Volume
- 93
- Issue
- 17
- Pages
- 236-254
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2335288327
- Cited by
- 303
- References
- 44
- FWCI
- 13.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bacillus Calmette-Guérin (BCG) Infection Following Intravesical BCG Administration as Adjunctive Therapy For Bladder Cancer: Incidence, Risk Factors, and Outcome in a Single-Institution Series and Review of the Literature. https://app.cochat.ai/papers/10.1097/md.0000000000000119
- The paper
- Pérez-Jacoiste Asín, M. A., Fernández-Ruiz, M., López-Medrano, F., Lumbreras, C., Tejido, Á., San Juan, R., Arrebola-Pajares, A., Lizasoain, M., Prieto, S., & Aguado, J. M. (2014). Bacillus Calmette-Guérin (BCG) Infection Following Intravesical BCG Administration as Adjunctive Therapy For Bladder Cancer: Incidence, Risk Factors, and Outcome in a Single-Institution Series and Review of the Literature. Medicine. https://doi.org/10.1097/md.0000000000000119
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.